In parallel, we have refined our trade show and conference strategy for 2026. Compared to prior years, we are placing greater emphasis on select national and regional meetings that consistently generate high quality leads and decision maker engagement, while reducing participation in lower yield events.

Feb 12, 2026 / receipt, needs a key / Michael Sardano, CEO | earnings call 2026-02-12 | transcript 83054b11-4348-4fa2-97a9-0c466d92c46b | chars 8156-8460 | segment 8

Yeah, absolutely. So some of them are going to be immediate. For instance, I'm actually traveling to Japan and Taiwan at the end of this month. So there's a Japanese-Taiwanese co-radiation meeting that's happening at the end of August. And I'll be going with our VP of International Affairs and meeting with the Japanese Radiation Regulatory Committee as well as the Taiwanese. And we already have an SRT100 vision that was sold last year, if you remember, to Taiwan. So the official ribbon cutting will be sometime soon. We're very excited about that, although they've been treating patients for over a year now. So I think that this is going to roll pretty quickly, especially in Asia, because of the China presence that we've had for the last 10 years. And it just boils over to that. And then South America, I think, will be shortly after. And as Joe mentioned, this greatly helps us in India as well and just gives us a backbone that we never had before in international. So we're pretty excited.

Aug 7, 2025 / receipt, needs a key / Michael, other | earnings call 2025-08-07 | transcript 1246344d-dcda-4f4e-831d-31080fb7af80 | chars 31755-32756 | segment 32

Selling and marketing expense was $1.4 million for the second quarter of 2025 compared with $1 million the second quarter of 2024. The increase was due to higher trade show expenses, higher costs related to clinical studies, and higher payroll costs due to an increase in headcount.

Aug 7, 2025 / receipt, needs a key / Javier Rampolla, CFO | earnings call 2025-08-07 | transcript 1246344d-dcda-4f4e-831d-31080fb7af80 | chars 10833-11115 | segment 11

Selling and marketing expenses decreased to $5 million from $5.6 million mainly due to lower agency fees, travel, and payroll.

Feb 5, 2025 / receipt, needs a key / Javier Rimpolla, CFO | earnings call 2025-02-05 | transcript d438ad50-c7ac-4eb6-b3a9-b9fc8961dcb5 | chars 12174-12300 | segment 12

Selling and marketing expense was $3.6 million for the first nine months of 2024, down from $5 million a year ago. The difference was primarily attributable to a decline in marketing agency expense, travel expense, and lower headcount.

Nov 14, 2024 / receipt, needs a key / Javier Rampolla, CFO | earnings call 2024-11-14 | transcript b1ceb232-fd39-4664-9023-161e24637c70 | chars 11613-11848 | segment 11

The lead on marketing expense for the fourth quarter of 2023 was 0.6 million compared with 1.6 million for the fourth quarter of 2022. The decrease was primarily attributable to lower compensation expense partially upset by higher trade show costs.

Feb 8, 2024 / receipt, needs a key / Javier Rampolla, CFO | earnings call 2024-02-08 | transcript e29befa4-c8e9-47a1-be88-53bc80414dab | chars 9661-9909 | segment 9

If one of the notes that you had from Javier that was increases in some expenses due to sales and trade shows, you know, we had the American Academy of Dermatology trade show was in a very expensive state, and then most recently Astro was in San Diego. If you know anything about the trade shows, Everything in the trade shows that have already been scheduled, we got the upcoming American Academy of Dermatology in March, also in San Diego. The actual costs to us, to any manufacturer, to exhibit in California is almost three times what it was two years ago. I mean, they've increased the cost tremendously. I'm not sure if we're going to continue to see a lot of these big societies continue to have their meetings in California because of those costs. But, I mean, we were as shocked as everybody else was when we showed up and we learned of the extra costs that were involved. So that's pretty much the difference in the expense that we've had in 2022 versus 2023 was just that one very show. But I would tell you we'd do it again only because the show was very valuable to us. We had as much activity at our booth at ASTRO, the American Society for Therapeutic Radiation, as we did several months earlier at the American Academy of Dermatology.

Nov 9, 2023 / receipt, needs a key / Joe Sardano, CEO | earnings call 2023-11-09 | transcript 564945c0-9cdf-45f9-889e-3ce1c0881d0f | chars 25975-27225 | segment 26

Selling and marketing expense for the first quarter of 2023 was $2.1 million compared with $1.2 million for the first quarter of 2022. The increase was attributable to higher trade show and advertising expense. Note that we have increased our participation in regional trade shows that are attended by our target customers These are considerably less expensive than large national shows and are an efficient way of using our cash.

May 3, 2023 / receipt, needs a key / Javier Rampolla, CFO | earnings call 2023-05-03 | transcript 0fdd84d5-4937-4ef6-bb5f-0aa8db6ca166 | chars 9848-10278 | segment 9

The increase was primarily due to higher professional fees and travel expense offset by a reduction in insurance expense.

May 3, 2023 / receipt, needs a key / Joe Sardano, CEO | earnings call 2023-05-03 | transcript 0fdd84d5-4937-4ef6-bb5f-0aa8db6ca166 | chars 10420-10541 | segment 10

As you know, we spend a great deal of time with our physicians, including key opinion leaders, at important medical conferences.

Aug 4, 2022 / receipt, needs a key / Joe Sardano, CEO | earnings call 2022-08-04 | transcript 06725d29-cbd6-4682-975e-9651c0cee965 | chars 4556-4684 | segment 4

While we continue to place utmost attention on expense management, the recent cash infusion from the sale of the non-core asset, plus the ability to access our revolving line of credit, puts Census in the strongest financial position in the company's history.

May 5, 2022 / receipt, needs a key / Javier, CFO | earnings call 2022-05-05 | transcript ea0b5d0b-f663-42cf-a8d5-57bd207f66a9 | chars 13291-13550 | segment 13

Selling and marketing expenses was $3.5 million for the first nine months of 2021, compared with $4 million for the first nine months of 2020. The decrease was primarily attributable to lower threshold expense due to cancellations related to COVID-19, reduced marketing activities including travel, and lower salary and benefit expenses due to reduced headcounts, partially offset by an increase in commission expense.

Nov 4, 2021 / receipt, needs a key / Javier Rampolla, CFO | earnings call 2021-11-04 | transcript f9ec8504-7b3f-4780-b655-b6f7bf7c1374 | chars 15105-15523 | segment 15